Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-04
2007-12-04
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000, C530S324000, C530S387100, C536S023100, C435S320100, C435S252300, C435S325000, C435S007100, C424S009100
Reexamination Certificate
active
10300072
ABSTRACT:
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 6171779 (2001-01-01), Chada et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 6677321 (2004-01-01), Levin
patent: 6720472 (2004-04-01), Chada et al.
patent: 7097838 (2006-08-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2003/0027260 (2003-02-01), Gooddard et al.
patent: 2003/0032090 (2003-02-01), Hardiman et al.
patent: 2003/0032674 (2003-02-01), Hwang
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0005316 (2004-01-01), Tracey et al.
patent: 2004/0053841 (2004-03-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 1 079 849 (2002-01-01), None
patent: 62-166897 (1987-07-01), None
patent: 10082788 (1998-03-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 00/47104 (2000-08-01), None
patent: WO 00/55174 (2000-09-01), None
patent: WO 00/75358 (2000-12-01), None
patent: WO 01/72993 (2001-04-01), None
patent: WO 01/36488 (2001-05-01), None
patent: WO 01/55386 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/089743 (2002-11-01), None
patent: WO 02/090520 (2002-11-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 03/022296 (2003-03-01), None
patent: WO 2004/004763 (2004-01-01), None
SWISS-PROT data base, accession No. P09429.
Falciola, L., et al., “High Mobility Group 1 Protein is not Stably Associated with the Chromosomes of Somatic Cells,”J Cell Biol. 137(1):19-26 (1997).
Sparatore, B., et al., “Extracellular High-Mobility Group 1 Protein is Essential for Murine Erythroleukaemia Cell Differentiation,”Biochem. J.32-:253-256 (1996).
Freeman, B. D., et al., “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies.” inInflammation: Basis Principals and Clinical Correlates(John I. Gallin and Ralph Snyderman eds., Lippincott, Williams & Wilkins, Philadelphia, 3rded. 1999), pp. 965-975.
Abaza, M.-S. I. and Atassi, M. Z., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J Protein Chem. 11(5):433-444 (1992).
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Biding of the Monoclonal Antibody, OKT4,”Mol Immunol. 28(11):1171-1181 (1991).
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”Res. Immunol. 145(1):33-36 (1994).
Abraham, E., et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”J. Immunol., 165:2950-2954 (2000).
Anderson, U., et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med., 192:565-570 (2000).
Bianchi, M.E., et al., “The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes) , Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”The EMBO Journal, 11(3): 1055-1063 (1992).
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins,”Trends Biochem. Sci., 26:152-153 (2001).
Degryse, B., et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells,”J. Cell Biol., 152:1197-1206 (2001).
Wang, H., et al., “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,”Science, 285:248-251 (1999).
Wang, H., et al., “Proinflammatory Cytokines (Tumor Necrosis Factor and Interleukin 1) Stimulate Release of High Mobility Group Protein-1 by Pituicytes,”Surgery, 126:389-392(1999).
Bustin, M., et al., “Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus,”J. Biol. Chem., 253(5):1694-1699 (1978).
Rauvala, H. and Pihlaskari, R., “Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons,”J. Biol. Chem., 262(34):16625-16635 (1987).
Daston, M. M. and Ratner, N., “Expression of P30, a Protein with Adhesive Properties, in Schwann Cells and Neurons of the Developing and Regenerating Peripheral Nerve,”J. Cell Biol., 112(6):1229-1239 (1991).
Parkkinen, J., et al. “Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides,”J. Biol. Chem., 268(26):19726-19738 (1993).
Sobajima, J., et al. “High Mobility Group (HMG) Non-Histone Chromosomal Proteins HMG1 and HMG2 are Significant Target Antigens of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Autoimmune Hepatitis,”Gut, 44:867-873 (1999).
Ma, E., et al. “Detection of Anti-Neutrophil Cytoplasmic Antibodies in MRL/Mp-lpr/lprMice and Analysis of Their Target Antigens,”Autoimmunity, 32:281-291 (2000).
Zhang, M. and Tracey, K. J., “Tumor Necrosis Factor,” inThe Cytokine Handbook, (Academic Press Limited), Third Edition, pp. 517-547 (1998).
Baxevanis, A. D. and Landsman, D., “The HMG-1 Box Protein Family: Classification and Functional Relationships,”Nucleic Acids Res., 23(9):1604-1613 (1995).
Sobajima, J., et al., “Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Ulcerative Colitis: Anti-Cathepsin G and a Novel Antibody Correlate With a Refractory Type,”Clin. Exp. Immunol., 105:120-124 (1996).
Uesugi, H., et al., “Prevalence and Characterization of Novel pANCA, Antibodies to the High Mobility Group Non-Histone Chromosomal Proteins HMG1 and HMG2, in Systemic Rheumatic Diseases,”J. Rheumatol., 25(4):703-709 (1998).
Passalacqua, M., et al., “Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation,”Neuroscience, 82(4):1021-1028 (1998).
Chou, D. K. H., et al., “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain,”J. Neurochem., 77:120-131 (2001).
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Ise, T., et al., “Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen,”Cancer Res., 59:342-346 (1999).
Jung, F., et al., “Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis,”Arthritis&Rheum., 40(10):1803-1809 (1997).
Bianchi, M. E., et al., “Specific Recognition of Cruciform DNA by Nuclear Protein HMG1,”Science, 243:1056-1059 (1989
Fink Mitchell P.
Tracey Kevin J.
Warren, Jr. Howland Shaw
Yang Huan
Hamilton Brook Smith & Reynolds P.C.
Kam Chih-Min
The Feinstein Institute for Medical Research
The General Hospital Corporation
University of Pittsburgh-Of the Commonwealth System of Higher Ed
LandOfFree
Use of HMGB fragments as anti-inflammatory agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of HMGB fragments as anti-inflammatory agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of HMGB fragments as anti-inflammatory agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886353